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ABSTRACT
The role of gene regulation in cancer: Studies of cancer-related phenotypes mediated
by MEX3D and by microRNA-618 implicate their potential oncogenic role

Travis Michael Whitfill

2014

The control of gene expression is pivotal in the context of molecular
pathogenesis of a number of diseases, and thus is of critical relevance to public health.
An array of cellular tools exist in controlling gene expression, including epigenetic
effects, non-coding RNAs, and RNA-binding proteins. These tools are critical to the
modern study of public health, and are used in tandem with population-based studies.
This work focuses on specific examples of non-coding RNAs and RNA-binding
proteins, describing the effects of microRNA-618, a non-coding RNA, and MEX3D,
a post-transcriptional regulator, in cancer.
MicroRNAs (miRNAs) form a class of highly conserved endogenous RNAs
that inhibit gene expression and may act as oncogenes or as tumor suppressors,
regulating extensive cancer-related gene networks. Here, we show the association
between a single miRNA, miR-618, and cancer-related pathways in HeLa cells. MiR618 was identified as a potentially oncogenic microRNA, controlling a number of
cancer-related gene networks and pathways. Gain-of-function analysis reveals
differential expression of 110 transcripts following miRNA-618 transfection. Notably,
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three upregulated genes are well-studied oncogenes—KIT, JUN, and FOSB—and
three downregulated genes are well-known tumor suppressors—PTPRO,
STK11/LKB1, and IGFBP5. Interestingly, investigation using the Ingenuity Pathway
Analysis software tool reveals alterations in multiple cancer-related and cell cyclerelated networks, including upregulated oncogenes in the top identified network
“Post-translational modification, cellular development, cellular growth and
proliferation” following miR-618 transfection. Further, miR-618 expression analysis
shows overexpression in HeLa cells compared to normal cervical cells. Our findings
present evidence for a novel oncogenic miRNA, miR-618, that is involved in cancerrelated gene networks and is overexpressed in cancer.
This work also examined the role of a novel post-transcriptional regulator,
MEX3D, in cancer. The Oncomine online database reveals that MEX3D is
overexpressed in a number of solid tumors, notably in glioma. MEX3D is 3.01-fold
overexpressed in glioma cells compared to non-cancerous, normal tissue. KaplanMeier survival analysis reveals that higher expression of MEX3D leads to poorer
overall survival in overall glioma patients. Lastly, in a pilot case-control study of
twelve glioma biopsies, we examined the effects of methylation in CpG sites in the
MEX3D gene. The results were unclear, as we found a 3’UTR site that was 9.5%
hypermethylated compared to normal tissue, a site in the body of the gene that was
24.8% hypermethylated, and second site in the body that was 15.4% hypomethylated
compared to normal tissue.
Phenotypic studies reveal that MEX3D is responsible for two cancer
phenotypes. Knockdown of MEX3D leads to increased cell proliferation and
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decreased cell invasion, suggesting that overexpression of MEX3D is responsible for
increased cell proliferation and decreased cell invasion.
This study is the first to describe the effects of miR-618 and of MEX3D in
cancer. The findings presented in this work lay the foundation for further mechanistic
studies of miR-618 and MEX3D. More work is needed to identify the mechanisms of
oncogenesis controlled by these molecules. Our study indicates that miR-618 may be
a biomarker for several types of cancer and warrants further investigation.
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CHAPTER 1: INTRODUCTION
The field of public health is changing. With the exponential decline of the cost
of whole-genome sequencing in tandem with explosive growth in research and
technology, we have seen a new paradigm emerge in public health research that
integrates population-based observations with complex data describing the
complexities of molecular mechanisms underlying complex diseases. No longer do
molecular research and traditional epidemiology need to remain separated. Rather, an
integrative approach is feasible—even warranted—and is gaining tractability and
popularity. This approach is much more powerful than a dis-integrated approach,
bridging gaps between medicine, bench-side research, and epidemiology, thus
providing a more relevant and 21st-century approach to studying diseases.
For the past decade, the genome-wide association study (GWAS) has been at
the forefront of genome-wide efforts to identify genetic variants that impact complex
human traits, providing key insights into the underlying allelic architecture of
complex human diseases. However, as we transition into what is commonly dubbed
the "post-GWAS" era of cancer genomics, and genome-wide initiatives move from
being novel to routine, it has become apparent that the main lesson learned from
GWAS efforts is that most cancer-associated genetic variants have only minor effects
on disease phenotype and, in total, explain only a small fraction of disease heritability.
This is due in part to the limited scope of genetic analyses that fail to account for the
complex interactions that occur between environmental stimuli and genetic and
epigenetic phenomena and in part due to the stringent statistical requirements inherent
to the GWAS.
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1.1 Function of microRNAs
One such epigenetic mechanism involves microRNAs (miRNAs), a group of
noncoding RNAs that have recently been found to silence genes post-transcriptionally.
miRNAs are small RNA molecules of 20-22 nucleotides that silence target genes by
either degrading the target mRNA or by preventing its translation.1 Surprisingly,
miRNAs have a large impact on genome-wide expression levels, as single miRNAs
have been shown to regulate expression of several hundred genes.2 It is estimated that
miRNAs control the expression of at least a third of all mRNAs in the human
genome.3 Thus, the role of miRNAs is fundamental in cellular processes, and aberrant
expression of these RNAs is tied to a number of diseases and many types of cancer,
including breast, colorectal, prostate, and lung cancer.3-7 The first identified miRNAs
in C. elegans, lin-4 and let-7 8
Since their discovery in the early 1990s, microRNAs have been thoroughly
investigated, and their role in gene expression has been well studied. MicroRNAs are
small RNA molecules of 20-22 nucleotides.1 The biogenesis of miRNAs is complex
and includes a number of proteins, including members of the Argonaute family,
polymerase II-dependent transcription, and RNAses Drosha and Dicer.9 After
transcription processing by the Drosha complex, the 60-110 nucleotide precursor
miRNA, or pre-miRNA, is then exported from the nucleus and is further processed by
Dicer and TAR RNA-binding protein 2 (TARBP2) to create the final 20-22
nucleotide mature, double-stranded miRNA in the cytoplasm.10 Once the mature
miRNA is formed, the antisense strand becomes incorporated into the miRNAcontaining RNA-induced silencing complex (mi-RISC) and guides the complex to its
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target mRNA. After hybridization between the miRNA and mRNA, the mRNA is
degraded and thus prevents gene expression. Surprisingly, miRNAs have a large
impact on genome-wide expression levels, as a single miRNA can downregulate
expression of several hundred genes.3

1.2 Role of miRNAs in cancer
The role of aberrant miRNA expression in cancer and other diseases has been
extensively investigated in the past 10 years. miRNAs are frequently located at fragile
sites in the chromosome and in genomic regions that have been linked to cancer.11
Importantly, miRNAs can have a role as either oncogenes or tumor suppressors
(collectively termed as oncomirs).3,9,12 Oncogenic miRNAs typically target tumor
suppressor genes, while tumor suppressive miRNAs usually repress oncogene
expression (See Figure 1.2). Aberrant miRNA expression is often due to
hypermethlated CpG islands proximal to the encoded miRNA.10 Notably, abnormal
miRNA expression has been found in almost all solid tumors and hematologic
malignancies.9,13,14 We and other groups have also identified associations between
single nucleotide variations in miRNAs and cancer.15,16
Due to their ability to modulate gene expression by post-translational
repression, miRNAs that target oncogenes (tumor-suppressive miRNAs) are essential
for maintaining stability and preventing tumorigenesis. However, it has been recently
discovered that when these miRNAs are aberrantly downregulated, there is an
increased risk of genomic instability, cell cycle aberrations, and possibly cancer. Thus,
certain cancers are likely to display a profile of differentially expressed microRNAs.
Following this discovery, several specific miRNAs have been identified that are
16

strongly downregulated in certain types of cancers. Conceivably, miRNAs could be
introduced into the cell as miRNA “replacement therapy,” thereby artificially
reversing the aberrant lack of presence of these regulatory RNAs (see Figure 1 for a
conceptual summary). Indeed, a number of recent studies have successfully
demonstrated efficacious treatment of cancers in vivo that support this “replacement
therapy” hypothesis.

1.3 Effects of DNA methylation in cancer
Gene expression is not determined solely by the DNA base sequence; it also
depends on epigenetic phenomena, defined as gene-regulating activities that do not
involve changes in DNA sequence whose effects may be inherited. 17 Epigenetic
control of gene expression occurs through two primary mechanisms: DNA
methylation (i.e., 5-methylcytosine content of DNA) and chromatin modification (i.e.,
the preservation of DNA protein complexes). Although epigenetic regulation of gene
expression has been known and studied for decades, little disease-related work was
done in this area until the close of the last century. Epigenetic regulation of gene
expression is a dynamic process, and the epigenetic status of a gene can change over
the lifetime of an organism. This ability to change and adapt in response to
developmental cues, environmental cues, or both rests primarily on post-synthetic
modifications either of the DNA itself (e.g., via methylation) 18 or of proteins that
intimately associate with DNA (e.g., the acetylation, methylation, or phosphorylation
of histones). 19 These modifications can then be interpreted by proteins (e.g., DNA
methyltransferases and histone deacetylases) that recognize a particular modification
and facilitate the appropriate downstream biological events.20
17

A major focus of epigenetic research has been the identification of CpG-rich
sequences, termed CpG islands, and the determination of methylation patterns within
these regions in relation to disease status. The most common post-synthetic
modification of the mammalian genome is the methylation of the 5’ position of
cytosines in dinucleotide CpG sequences. Approximately 60–90% of all dinucleotide
CpG sequences in the genome are methylated, while unmethylated dinucleotides are
mainly clustered in CpG islands in gene promoters.21 Although the addition of a
methyl group does not alter base pairing, it can impinge on protein-DNA interactions
via the attenuation of binding affinity of sequence-specific DNA binding proteins for
their cognate cis elements and result in changes in chromatin structure and histone
acetylation status. 22 Normally, both the core promoter and transcription start site are
located within the CpG island, and gene expression is completely repressed when this
region becomes hypermethylated. As such, the predominant role of DNA methylation
encompasses a wide range of functions, including developmental and tissue-specific
gene transcription,23,24 imprinted gene expression,25 expression of transposable
elements,26 chromatin organization 27 and suppression of integrated foreign DNA.28,29
The relative plasticity of epigenetic mechanisms makes the study of epigenetics a
powerful paradigm in the investigation of disease etiologies. In particular, epigenetics
may offer an opportunity to further our understanding of a number of features of
complex diseases that traditional DNA sequence–based genetics has been unable to
explain.30

1.4 RNA binding proteins and disease relevance

18

RNA-binding proteins (RBPs) form a class of highly evolutionarily conserved
post-transcriptional regulators found in a variety of organisms. Nascent mRNAs
associate with RBPs during transcription to form messenger ribonucleoprotein
(mRNP) complexes. RBPs direct and control the localization, stability, or translation
of their target RNAs.31 Recent studies underscore the importance of such proteins in a
variety of physiological functions, including stem cell differentiation, embryogenesis,
and cancer.32 Most RBPs recognize the secondary structures formed by their target
mRNA, but are also able to recognize certain intrinsic features of RNA such as
certain sequence motifs, the 5’ cap or the 3’ poly (A) tail. Furthermore, RBPs are
involved in miRNA stabilization and processing, and disruption between the interplay
between miRNA and RBPs have clear implications in cancer.33,34
Recent high throughput techniques such as photoactivatable-ribonucleosideenhanced UV crosslinkning and immunoprecipitation (PAR-CLIP), iCLIP, and CLIPseq have identified the mRNA-bound proteome.35-37 From these advanced techniques,
more than 800 mammalian RBPs with over 40 RNA-binding domains (RBDs) for
recognition of secondary structures of specific sequence motifs have been
identified.31,32 This includes RNA recognition motifs (RRMs), the K-homology (KH)
domain, double-stranded RNA binding motif (dsRBM), the Arg-Gly-Gly (RGG) box,
DEAD/DEAH box, and Piwi/Argonaute/Ziwi (PAZ) domains.38 KH domains are
important motifs in RNA-binding activity, and a number of studies have elucidated
the importance of the motif’s function in RNA binding and gene regulation.39,40
Many RBPs are relevant to a number of diseases, particularly in cancer. For
example, the RBP insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is
19

upregulated in several types of cancer, and has been shown to display oncogenic
activity through binding and stabilizing c-MYC and MK167 mRNA.41 Other
members of the IGF2BP family such as IGF2BP2 and IGF2BP3 have been shown to
be post-transcriptional drivers of cancer progression and can regulate important
drivers in cancer including β-catenin, let-7 microRNA, KRAS, and MDR1.41-44

1.5 MEX-3
MEX-3 is a translational repressor and RNA-binding proteins originally
discovered in C. elegans. Vertebrates have four MEX-3 analogues, and are highly
evolutionarily conserved across species. The MEX-3 family plays an important role
in a number of cellular functions, but most recently they have been found to play a
central role in cell differentiation and cell renewal, and are thus of major concern to
stem biology and cell biology.45
Studies in C. elegans underscore the importance of MEX-3 in embryonic
development. Mutations in Mex-3 are embryonic lethal and cause defects in the AB
anterior blastomere descendants, particularly in the body wall muscle, thus the name
muscle excess 3 for Mex-3.46 In oocytes, Mex-3 is uniformly distributed, but becomes
asymmetrically overexpressed in the two anterior blastomeres at the four-cell stage.47
MEX-3 targets PAL-1 in the PAL-1 3’UTR and prevents its translation in the anterior
blastomeres.48,49 Thus, MEX-3 spatially represses PAL-1. PAL-1 is necessary for
establishing the posterior blastomeres. In addition to its role in establishing the
anterior blastomeres MEX-3 is also involved in ensuring segregation of P granules at
the eight-cell stage.46 P granules contain maternal mRNAs and are thought to be
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involved in determining the germline.47 Thus, this function suggests the importance
of MEX-3 in establishing the specification of this cell lineage.
Importantly, MEX-3 family members are highly evolutionarily conserved
across species. Phylogenetic analysis reveals that ancestral mex-3 underwent two
round of duplication after vertebrate lineage divergence, which accounts for the
presence of four homologues in both mice and humans.50 MEX-3 contains two K
homology (KH) domains that contain RNA-binding activity. The structure of the KH
domain bound to its target RNA is shown in Figure 1.3. However, vertebrates contain
an additional domain, perhaps a neo-functionalization that may have arisen during
species divergence, the carboxy terminus really interesting new gene (RING) finger
domain, which is absent in C. elegans. RING domains have been shown to mediate
E3 ubiquitin ligase activity. Such activity has been shown in MEX-3C, which is
responsible for degradation of human leukocyte antigen serotype A2 (HLA-A2)
mRNA.51

1.6 Disease relevance of MEX-3 family
While the primary function of MEX-3 proteins in humans is unknown, recent
evidence suggests they carry a role in cancer and other diseases, including
hypertension, metabolic diseases, and cancer.52-54 Interestingly, MEX3A
overexpression in an intestinal cell line lead to impaired differentiation and altered
polarity.55 Further, MEX-3 in C. elegans represses cell-cycle inhibitor cyclindependent kinase inhibitor-2 (CKI-2)56, whose human orthologues p21, p27, and p57
contain tumor suppressive activity.45 Furthermore, silencing of MEX-3C causes
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chromosome mis-segregation, structural abnormalities, and DNA replication stress.45
Data from the Oncomine database (http://www.oncomine.com) strengthens the
possible role of MEX-3 family members in cancer, as there are large amounts of data
that suggest its overexpression in cancer compared to normal tissue.
MEX-3D, a member of the hMEX-3 family, is expressed in somatic tissue in
humans, contrasting with the expression profile of its analogues, which are restricted
to the embryo and the germ line. Interestingly, the Oncomine database reveals that
MEX-3D is highly overexpressed in a number of cancer samples compared to normal
tissue. Yet, there is a gross lack of understanding of the role of this protein in both
normal cell physiology and in cancer. As such, we aimed to elucidate these roles by
with an emphasis on glioma. The success of this project would have profound
implications both in cancer biology and in the clinical relevance of these proteins, as
they could serve as potential biomarkers or candidates for gene therapy in breast
cancer.
Despite gaining recent momentum in research, there is a gross lack of
understanding of the role of these proteins. Namely, there are four major deficits in
MEX3 family research (adapted by Pereria et al. 201345): (1) Identification of RNA
targets and mechanism or recognition and regulation; (2) Distinction of functional
redundancy between MEX-3 family members; (3) Determination of interactions
between signaling pathways and molecular processes; and (4) Analysis of
physiological and pathological roles, especially in cancer.
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Interestingly, the Oncomine database reveals that MEX-3D is highly
overexpressed in a number of cancer samples compared to normal tissue. Yet, there is
a gross lack of understanding of the role of this protein in both normal cell physiology
and in cancer. The goal of this study was to determine the effects of MEX3D in
glioma.

1.7 Epidemiology and clinical characterization of glioma
Malignant brain tumors comprise a frightening and deadly diagnosis. Little
advances in this area have improved outcomes. An estimated 138,000 patients were
newly diagnosed with a primary malignant brain tumor in the United States in 2010.57
Dismally, the 5- 10- and 20- year overall survival rates for all gliomas are 54%, 45%,
and 40%, respectively.57 The World Health Organization (WHO) classification
system categorizes glioma into four distinct histological grades differentiated by
increasing degrees of dedifferentiation, anaplasia, and aggressiveness.58 Grade III
tumors include astrocytomas, oligodendroglioma, and oligoastrocytoma.58 Grade IV
tumors, or glioblastoma, account for 82% of cases of malignant glioma and are
defined histologically by considerable cellularity, mitotic activity, vascular
proliferation, and necrosis.59 Sadly, the 5-year survival rate for glioblastoma is
4.7%.60
Malignant gliomas arise from sequential genetic alterations from intrinsic and
environmental influences. Contrary to public perception, risk factors for glioma do
not include exposure to cell phones.59,61,62 These studies are limited by a number of
factors including recall bias, inconsistent measurement of cell phone usage, and
varying cell phone technologies over time. Established risk factors for glioma are
23

limited, but include ioninizing radiation.63,64 Gliomas are most common later in life,
especially in the sixth to eighth decade of life.59 Family history has a moderate
influence on risk for glioma and is associated with about a 2-fold increase in risk of
developing glioma.59 Genome-wide association studies have identified a few genes
that are weakly associated with glioma, including 0q13.33 (RTEL), 5p15.33 (TERT),
9p21.3 (CDKN2BAS), 7p11.2 (EGFR), 8q24.21 (CCDC26), and 11q23.3
(PHLDB1).65,66
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Figure 1.1 Role of miRNAs in gene expression
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Figure 1.1 Role of miRNAs in gene expression
miRNA silences translation of a gene through post-transcriptional targeting. First, the
target gene is transcribed in the nucleus. Once exported into the cytoplasm, the
miRNA binds to the target mRNA, usually in the 5’UTR region. This blocks the
translation of the mRNA by preventing binding of translational machinery and thus
preventing the encoded protein from being translated. It is important to note that a
single miRNA can have up to hundreds of targets through non-specific binding.
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Figure 1.2 Role of miRNAs in molecular carcinogenesis
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Figure 1.2 Role of miRNAs in molecular carcinogenesis
miRNAs can act as either oncogenes or tumor suppressor genes. Oncogenic miRNAs
typically silence translation of tumor suppressors and the expression of these
miRNAs remains at a relatively low level of expression in normal cells. However, if
overexpressed, they can inhibit translation of tumor suppressors, leading to decreased
tumor suppressor expression, and increased likelihood of carcinogenesis (a).
Conversely, tumor suppressive miRNAs typically inhibit expression of oncogenes.
When these miRNAs are underexpressed, they lead to overexpression of tumor
suppressors, thus potentially leading to carcinogenesis (b).
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Figure 1.3 Schematic of mRNA in humans and regulation of post-transcriptional
activity
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Figure 1.3 Schematic of mRNA in humans and regulation of post-transcriptional
activity
The generic structure of a eukaryotic mRNA, illustrating some post-transcriptional
regulatory elements that affect gene expression. Abbreviations (from 5’ to 3’): UTR,
untranslated region; m7G, 7-methyl-guanosine cap; hairpin, hairpin-like secondary
structures; RBP, RNA-binding protein; uORF, upstream open reading frame; IRES,
internal ribosome entry site; mRNP, messenger ribonucleoprotein; CPE, cytoplasmic
polyadenylation element; AAUAAA, polyadenylation signal. Based on Mignone et al.
2012.67
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Figure 1.4 3D structure of the KH domain
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Figure 1.4 3D structure of the KH domain
The structure was adapted by Lewis et al. 2000.68 It shows the Nova-2 KH3-RNA
complex. The structures highlight the dimeric assembly of the KH domains.
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CHAPTER 2: MIR-618 DISPLAYS POSSIBLE ONCOGENIC ACTIVITY

2.1 INTRODUCTION
One newly identified miRNA, hsa-miR-618, is located in the chromosomal
region 12q21.31.22 Interestingly, an increased risk for prostate cancer has been
associated with low copy number variation with this region.69 Also, two recent studies
have suggested a possible role of miR-618 in cancer. One study identified a single
nucleotide polymorphism in miR-618 and found a weak, non-significant positive
association with risk of breast cancer.15 A second recent study identified miR-618 as a
possible biomarker for hepatocellular carcinoma among patients infected with
Hepatitis C.16 Yet, these findings have not been supported, and the potential role of
miR-618 in cancer remains unclear.
In order to elucidate the role miR-618 plays in cancer, we investigated the
differential gene expression associated with miR-618 transfection into cultured cells
using genome-wide expression microarray analysis. After the gene expression levels
were obtained, significantly altered transcripts were investigated for network and
functional interrelatedness using the Ingenuity Pathway Analysis software tool. Our
study indicates a strong correlation between miR-618 and cancer-related networks
and genes. Three common oncogenes were upregulated—i.e. JUN, FOSB, and KIT—
while three tumor suppressor genes were downregulated as a result of the transfection,
PTPRO, IGFBP5, and STK11 (this will henceforth referred to as LKB1). Furthermore,
we observed a number of genes involved in hepatotoxicity and hepatocellular
carcinoma, which supports the recent study that found an association between
aberrant miR-618 expression and hepatocellular carcinoma. Finally, we found an
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overexpression of miR-618 in HeLa cells compared to non-cancerous End1 cervical
cells. Overall, our results seem to implicate an oncogenic role for miR-618, and as
such, warrant further investigation.

2.2 RESULTS
Effect of genome-wide expression levels by miR-618 transfection
The microarray assay determined genome-wide expression in miR-618
transfected cells compared with cells transfected with the scrambled control. 110
identified transcripts fit our criteria for significance (Q < 0.05 and fold change ≥ |2|).
Of these 109 transcripts, 79 showed increased expression (fold change ≥ 2), and 30
transcripts showed decreased expression (fold change ≤ -2). The predicted secondary
structure of pre-miR-618 is shown in Supplementary Figure S1, and an exhaustive
list of all significantly differentially expressed genes can be found in Supplementary
Table 1.

Cancer-related networks formed by miR-618-mediated genes
To determine which biological functions and networks may be influenced by
miR-618, we examined the set of genes with altered expression using the Ingenuity
Pathway Analysis software tool. We identified eight biological groups of molecules
that contained at least ten differentially expressed transcripts. Cancer is the top
biological-related function associated with miR-618 transfection, involving 29
differentially expressed genes (p-value <0.05). Other identified functions include
immunological disease (22 genes), organismal injury and abnormalities (10 genes),
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cellular movement (16 genes), cellular development (16 genes), cellular growth and
proliferation (20 genes), cell cycle (11 genes), and cell death (19 genes) (p-values
<0.05). These biologically relevant functions are summarized in Table 1, and the
cancer-related transcripts are summarized in Table 2 and detailed in
Supplementary Table S2. Furthermore, differentially expressed transcripts were
associated with a number of cancer-associated functions. In addition to the genes
identified related to cancer, cell cycle, cell death, and cellular growth and
proliferation, we also identified significant associations with tumor morphology (4
molecules), and DNA repair (7 molecules). These cancer-related functions are
summarized in Figure 1.
The top network identified, “Post-translational modification, cellular
development, cellular growth and proliferation”, consists of 11 overexpressed
transcripts (ANG, DCN, FGFBP1, FOSB, HMGB1, JUN, KIT, KRT18, MIF, PCDH1,
and PDGFRB) and 5 underexpressed transcripts (CBX5, IGFBP5, PDGFRA, PTPRO,
and LKB1). Importantly, several of these upregulated genes, namely FOSB, JUN, and
KIT, are well known oncogenes. Known functions and respective fold changes of
genes in this network are summarized in Table 2. Figure 2 presents the peptides
encoded by these genes in their respective locations of function in the cytoplasm,
nucleus, cell membrane, or extracellular space. The second top network identified
was “Cellular movement, cell death and survival, and cell cycle.” The software
identified eight overexpressed transcripts (SGK3, EDN2, HUWE1, IFI27, MAPK4,
MIF, NUDCD2, and TM4SF1) and two underexpressed transcripts (C1QTNF5 and
CLDN5). Supplementary Figure S2 presents a graphical representation related to
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this network. All microarray expression data have been uploaded to the Gene
Expression Omnibus (GEO) database, and can be accessed via their website
(http://www.ncbi.nlm.nih.gov/geo/; accession # pending).

Overexpression of miR-618 in Hela cells
In order to determine if miR-618 is overexpressed in cancer compared to
normal tissue, we performed an expression analysis in miR-618 non-transfected HeLa
cervical cancer cells relative to End1 cervical cells. The expression analysis in HeLa
cells revealed an overexpression of miR-618 by 2.68-fold relative to End1 cells
(Figure 3).

2.3 DISCUSSION
The importance of miRNAs in regulating and maintaining a variety of cellular
functions is widely known and studied. Certain miRNAs carry the potential for either
oncogenic or tumor suppressive activity, and can regulate cancer-related gene
networks. After analyzing the effects of miR-618 transfection on genome-wide
expression levels in HeLa cells, we report here the oncogenic role of miR-618 and its
regulatory impact on cancer-related gene networks. miR-618 is located in the
12q21.31 region, and interestingly, an increased risk for prostate cancer has been
associated with low copy number variation in this region.69 The gene MGAT4C also
maps to 12q21.31, and its copy number variation has been associated with prostate
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Recently, our group has described the effects of miR-618 in non-Hodgkin
lymphoma.70 A total of 128 miR-618 targets were identified that were enriched for
genes that have functional roles in lymphoma-relevant pathways. The study also
revealed a significant association between rs2682818 G>T in the miR-618 and
follicular lymphoma (FL) (OR: 1.65, 95% CI: 1.05-2.60). In vitro analysis of
rs2682818 functional impact revealed that the variant T allele resulted in reduced
levels of mature miR-618, which in turn may lead to deregulation of miR-618controlled pathways relevant to follicular lymphoma.
We identified three overexpressed oncogenes from the miR-618 transfection.
JUN, FOSB, and KIT are commonly studied oncogenes and were upregulated by fold
changes of 2.79, 3.62, and 2.20, respectively (Q-values <0.05). These genes all
belong to the top identified network “Post-translational modification, cellular
development, cellular growth, and proliferation.” Notably, FosB has been
demonstrated to lead to increased cell invasion in MCF7 cells.71 Together, FosB and
Jun form a heterodimer and are both highly overexpressed in a variety of cancers.72
The Jun/FosB complex is essential for regulating a number of cancer-related
functions, including invasion and metastasis, cell proliferation, cell differentiation,
angiogenesis, and cell survival.73 Further, the c-Kit receptor, a transmembrane protein,
is a notable member of the type III receptor tyrosine kinase family and also regulates
similar biological functions as Jun/FosB, including cell proliferation, cell
differentiation, cell development, and cell migration.74 Overexpression or abnormal
regulation of c-Kit has been strongly linked to cancer.75 Thus, miR-618 carries
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important oncogenic activity by upregulating these oncogenes involved in
mechanisms central to cancer and tumorigenesis.
PTPRO, IGFBP5, and LKB1 were significantly underexpressed tumor
suppressors following miR-618 transfection with fold changes of -2.07, -2.02, and 2.38, respectively (Q-values <0.05). PTPRO encodes a protein tyrosine phostphatase
receptor that is involved in proper entry into the G1 phase and regulates apoptotic
pathways.76 Loss-of-function of this receptor is highly associated with cancer.76
IGFBP5, which encodes an insulin-like growth factor binding protein, is another
important protein in cancer that is essential in inhibiting mitogenesis, cell
differentiation, and in preventing metastasis.77,78 Aberrant IGFBP5 expression has
been documented in a number of cancers. LKB1 encodes an important
serine/threonine kinase-activating kinase in which loss-of-function leads to PeutzJehers syndrome and sporadic cancers such as lung and cervical cancer.79 LKB1 plays
a role in phosphorylation cascades that regulate essential cellular processes such as
cytoskeleton organization, cell proliferation, and metabolism.79 This strengthens
support of the putative role of miR-618 in cancer, as the loss of tumor suppressor
genes and overexpression of oncogenes is a common phenotype in nearly all cancers.
Importantly, a recent study found a significant association between
upregulated miR-618 expression and hepatocellular carcinoma (HCC) among
Egyptian patients infected with Hepatitis C virus (HCV),80 identifying miR-618 as a
potential risk biomarker for HCC. Interestingly, our IPA analysis found an
upregulated gene that is associated with hepatocellular carcinoma, IL22RA, due to
miR-618 transfection. IL22RA is directly associated with carcinoma and carcinoma in

38

situ. More importantly, IL22RA is found within the same interaction network as IL22,
which is associated with hepatocellular carcinoma and liver tumorigenesis,
proliferation, hyperplasia, and hypertrophy (all p-values <0.05). Furthermore, we
identified seven molecules associated with hepatotoxicity and hepatocellular
carcinoma that were differentially expressed: TM4SF1, KIT, PDGFRB, HUWE1,
HMGB1, PTPRO, PDGFRA, and MATN3 (p-value = 5.72 x 10-3; see Supplementary
Table S1 for more information). PTPRO has been associated with hepatocellular
carcinoma progression when underexpressed, and exhibited a -2.07-fold change in
expression (Q<0.05) following miR-618 transfection.81 Thus, taken in the context of
miR-618 as a biomarker for hepatocellular carcinoma, our analysis implicates miR618 as a potential upstream effector of hepatocellular carcinogenesis via its
interactions with genes relevant to HCC proliferative and hepatotoxicity pathways.
Interestingly, an A>C single nucleotide polymorphism (SNP), rs2682818, has
been identified in miR-618 that may be involved in cancer. According to the NCBI
SNP database, the hsa-miR-618 SNP variant (C to A) has been most commonly found
among Japanese and African American individuals, and least common among
Caucasians (A genotype frequency 0.320, 0.320, and 0.170, respectively).82 A study
by Zhang et al. recently investigated the role of this SNP in miR-618 in breast cancer
among Chinese females, but found no significant association.15 However, the study
was limited due to its small sample size, thus further investigation is necessary to
explore the potential role of the SNP in miR-618 in tumorigenesis in breast cancer
and in other cancers. A study in 2010 by Cicatiello et al. identified miR-618 as a
target of 17β-estradiol in estrogen-responsive breast cancer MCF-7 breast cancer
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cells.83 The findings both associate miR-618 in breast cancer and demonstrate that
miR-618 is responsive to estrogen control of target gene activity. These studies
support our findings by providing a possible role of aberrant miR-618 expression in
breast cancer specifically.
As with all in vitro studies, there are several limitations in this study. As the
miR-618 transfection was conducted in HeLa cells, the findings are limited to genes
with detectable expression levels in this cell line. HeLa cells have a gene expression
profile that differs from those of other cell lines, and, as such, it is likely that some
observed expression changes may be HeLa-specific. Further, since we determined
following the transfection and network analysis that miR-618 is upregulated in HeLa
cells compared to End1 cells, the results may have been more meaningful in a cell
line in which miR-618 was not overexpressed. Nevertheless, our findings indicate a
strong potential role for miR-618 in cancer. In combination with the previous
suggestion of miR-618 as a potential biomarker for hepatocellular carcinoma,
evidence strongly supports a possible role of this miRNA in hepatocellular carcinoma,
liver cancer, and other diseases. A number of future studies are warranted based on
our results, including an expansion of this analysis to other cell lines, and an
investigation of the role of this miR-618 in clinical samples.
As previous evidence regarding the role of the novel miRNA miR-618 in
cancer remains unclear, we present evidence that miR-618 may serve an important
role in cancer, finding that it affects the expression of key oncogenes and tumor
suppressors and that it operates in cancer-related pathways. Our observations of miR618 overexpression in cancer cells support an oncogenic role of miR-618. Taken
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together with our findings of overexpressed oncogenes and underexpressed tumor
suppressor genes following miR-618 transfection, miR-618 is a likely oncomir. Our
data indicate that when overexpressed, miR-618 may carry an oncogenic role by
modulating pathways leading to increased cell growth, cell migration, cell invasion,
and cell proliferation. Notably, our findings suggest a role for miR-618 in
hepatocellular carcinoma, as a number of genes associated with hepatocellular
carcinoma and hepatotoxicity were dysregulated as a result of the miR-618
transfection. Further in vitro and in vivo studies are warranted to validate and
elucidate the association between miR-618 and cancer and to determine the clinical
relevance of miR-618 as a possible biomarker in cancer.
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Table 2.1 Top biological functions of differentially expressed target genes of miR618
Name

No. of molecules

P-valuea

Cancer

29

8.61 x 10-7

Immunological disease

22

8.61 x 10-7

Organismal injury and abnormalities

10

8.61 x 10-7

Cellular movement

16

2.95 x 10-4

Cellular development

16

3.89 x 10-2

Cellular growth/proliferation

20

3.89 x 10-4

Cell cycle

11

1.55 x 10-3

Cell death

19

2.04 x 10-3

`a

P-values represent the pooled value of the target genes and were calculated with the
Fisher t-test.
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Table 2.2 Identified cancer-related differentially expressed miR-618 targets
Gene name

Expression fold
changesa

Gene name

Expression
fold changes

ANG

2.25

IL22RA1

2.52

ANXA8L2

2.19

JUN

2.79

BIK

2.66

KCNE4

2.75

C8ORF8/SGK1

2.17

KIT

2.20

CDH7

2.26

KRT18

2.99

CLDN5

-2.47

MAFA

-2.02

DCN

2.35

MATN3

-2.70

DESI2

2.22

MIF

2.01

FGFBP1

2.03

MX1

2.04

FOSB

3.62

PDGFRA

-2.10

HMGB1

2.04

PDGFRB

2.04

HUWE1

2.04

RNASE4

2.01

IFI27

2.14

STK11/LKB1

-2.38

IGFBP5

-2.02

TM4SF1

3.16

a

All fold changes have a Q value of <0.05.

43

Figure 2.1 Cancer-related functions of selected differentially expressed genes
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Figure 2.1: Cancer-related functions of differentially expressed transcripts.
Seven biological functions associated with cancer were identified using the IPA
software: cancer, cell growth and proliferation, cell cycle, cell death, tumor
morphology, gene expression, and DNA repair. The left y-axis indicates the number
of identified molecules for each function represented by the bars. The right y-axis
indicates the –log of the pooled p-values for each function, represented by the marked
line. The statistical significance threshold of –log(p=0.05) is given by the straight line.
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Figure 2.2 Differentially expressed genes in the “Post-translation modification,
cellular development, and cellular growth and proliferation” network
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Figure 2.2 Differentially expressed genes in the “Post-translational modification,
cellular development, and cellular growth and proliferation” network
Network of differentially expressed transcripts following miR-618 transfection under
the “post-translational modification, cellular development, and cellular growth and
proliferation” network. This network was identified by the Ingenuity Pathway
Analysis software as significantly associated with the set of transcripts with altered
expression following the introduction of the miR-618 mimic (pooled p-value = 8.61 x
10-7 and FDR ≥ |2|). Overexpressed transcripts are indicated in red, and
underexpressed transcripts are indicated in green. Transcripts indicate the relative
location by either in the nucleus, cytoplasm, cell membrane, or extracellular matrix.
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Figure 2.3 miR-618 is overexpressed in HeLa cells relative to End1 cells.
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Figure 2.3 miR-618 is overexpressed in HeLa cells relative to End1 cells
qPCR results of quantifying miR-618 levels in HeLa cells relative to End1 cells
reveals a 2.68 fold change in cancer vs. non-cancer cells. Expression levels were
quantified using the 2-∆∆Ct method with normalization to the stably expressed ncRNA
U6B, where ∆∆Ct = (Ct:miR-618_HeLa – Ct:U6B_HeLa) – (Ct:LmiR-618_End1 – Ct:U6B_End1). Error
bars represent the standard deviation of the CT values.
cancer among Caucasian males (OR = 4.8, p = 2.6 x 10-3), thus highlighting the
importance of this genetic region in cancer.69
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CHAPTER 3: MEX3D IS OVEREXPRESSED ACROSS CANCER TYPES

3.1: INTRODUCTION
RNA-binding proteins (RBPs) form a class of highly evolutionarily conserved
post-transcriptional regulators found in a variety of organisms. Recent studies
underscore the importance of such proteins in a variety of physiological functions,
including stem cell differentiation, embryogenesis, and cancer.32 MEX-3 is a
translational repressor and RNA-binding proteins originally discovered in C. elegans.
Vertebrates have four MEX-3 analogues, and are highly evolutionarily conserved
across species. The MEX-3 family plays an important role in a number of cellular
functions, but most recently they have been found to play a central role in cell
differentiation and cell renewal, and are thus of major concern to stem biology and
cell biology.45
Importantly, MEX-3 family members are highly evolutionarily conserved
throughout species. Phylogenetic analysis reveals that ancestral mex-3 underwent two
round of duplication after vertebrate lineage divergence, which accounts for the
presence of four homologues in both mice and humans.50 MEX-3 contains two K
homology (KH) domains that contain RNA-binding activity. However, vertebrates
contain an additional domain, perhaps a neo-functionalization that may have arisen
during species divergence, the carboxy terminus really interesting new gene (RING)
finger domain, which is absent in C. elegans. RING domains have been shown to
mediate E3 ubiquitin ligase activity. Such activity has been shown in MEX-3C, which
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is responsible for degradation of human leukocyte antigen serotype A2 (HLA-A2)
mRNA.51
While the primary function of MEX-3 proteins in humans is unknown, recent
evidence suggests they carry a role in cancer and other diseases, including
hypertension,

metabolic

diseases,

and

cancer.52-54

Interestingly,

MEX3A

overexpression in an intestinal cell line lead to impaired differentiation and altered
polarity.55 Further, MEX-3 in C. elegans represses cell-cycle inhibitor cyclindependent kinase inhibitor-2 (CKI-2)56, whose human orthologues p21, p27, and p57
contain tumor suppressive activity.45 Furthermore, silencing of MEX-3C causes
chromosome mis-segregation, structural abnormalities, and DNA replication stress.45
However, the overall function of MEX3 proteins in humans is largely unknown,
especially in the context of cancer development. As such, this study aimed to profile
the expression of MEX3D as well as the other members of the MEX3 family,
MEX3A-C, in a number of tumors compared to normal tissue in order to guide
molecular studies presented in Chapter 4.
Case-control

studies

deposited

in

the

Oncomine

database

(http://www.oncomine.com) reveal that MEX3 family members are highly
overexpressed in many types of cancer. In particular, we show here that MEX3D is
overexpressed in melanoma, sarcoma, glioma, pancreatic cancer, cervical cancer,
colorectal cancer, lymphoma, gastric cancer, and oral cancer. These findings are
crucial, as they point to clear evidence that MEX3 family members play a role in
tumor development. Future studies are needed to understand the mechanistic role of
the proteins.
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3.2 RESULTS

MEX3D is overexpressed in many types of cancer

According to the Oncomine database, MEX3D is overexpressed in five types
of gastrointestinal cancers. In gastric cancer, there was a fold change of 2.52 (p =
2.03x10-8) in MEX3D measured in 31 paired gastric carcinoma and adjacent normal
gastric mucosa. The results are from a human genome U133 Plus 2.0 Array.84 70
colorectal carcinoma and 12 normal colon samples were analyzed with the U133 Plus
2.0 Array. There was a 2.59-fold change in colorectal cancer vs. normal samples (p =
2.04x10-8).85 In pancreatic cancer, 36 pancreatic carcinoma and 16 paired normal
samples were analyzed with the Human Genome Plus 2.0 Array. The analysis
revealed that MEX3D is 2.88-fold overexpressed in pancreatic cancer vs. normal
tissue (p = 1.89x10-9).86 Another study looked at 7 rectal adenoma samples and 25
colon adenoma samples matched with 32 normal samples using the U133 Plus 2.0
Array. The study found that MEX3D is 2.76-fold overexpressed in rectal adenoma vs.
normal tissue (p = 9.33x10-6) and 2.09-fold overexpressed in colon adenoma vs.
normal tissue (p = 5.76 x 10-11).87
MEX3D was also overexpressed in skin cancer. The gene expression analysis
in melanoma included 45 cutaneous melanoma samples, 18 benign melanocytic skin
samples, and 7 normal skin samples analyzed with the U133 Plus 2.0 Array. The
analysis revealed that MEX3D is overexpressed 2.42-fold in benign melanoma vs.
normal skin (p = 2.58x10-6), and 4.41 in cutaneous melanoma vs. normal skin (p =
6.96x10-9).88
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The Oncomine database also reveals that MEX3D is overexpressed in at least
two reproductive cancers. In prostate adenocarcinoma, using 69 prostate tumor
samples, 18 adjacent normal prostate samples, and 2 pooled normal prostate samples
with the U133 Plus 2.0 Array, MEX3D was found to be overexpressed in prostate
tumor vs. normal tissue by 2.10-fold (p = 9.70x10-4).89 In cervical cancer, 20 cervical
cancers were used with 8 cervical normal samples using the U133 Plus 2.0 Array. The
study found MEX3D was overexpressed in cervical cancer vs. normal tissue by 2.80fold (p = 2.43x10-7).
Five types of sarcomas showed overexpression of MEX3D compared to
normal tissue. In a study of 149 soft tissue sarcomas compared to 9 normal adipose
tissue specimens, MEX3D was overexpressed 3.11-fold in pleomorphic liposarcoma
vs. normal was (p = 5.51x10-8), 2.99-fold in myxofibrosarcoma vs. normal (p =
2.82x10-10), 2.33-fold overexpressed in dedifferentiated liposarcoma vs. normal (p =
4.28x10-8), and 2.73 in myxoid/round cell liposarcoma vs. normal tissue (p = 9.35x108 90

).

In a separate study of 39 sarcoma samples and 15 normal tissue samples using

the Human Genome U133A Array, MEX3D was overexpressed by 3.02-fold in
fibrosarcoma vs. normal tissue (p = 5.48x10-6).91
A few other types of cancer also exhibited overexpression of MEX3D
compared to normal tissue. Tongue cancer, a form of oral cancer, exhibits a 2.12-fold
overexpression compared to normal tissues (p = 2.11x10-4).92 The study used 42 head
and neck cancers compared to 14 head and neck normal samples on the Human
Genome U133 Plus 2.0 Array. MEX3D was also 2.84-fold overexpressed in germinal
center B-cell-like diffuse large B-cell lymphoma vs. normal (p = 4.85x10-5), 2.37-
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fold overexpressed in activated B-cell-like diffuse large B-cell lymphoma vs. normal
(p = 1.45x10-8), and 2.35-fold overexpressed in diffuse large B-cell lymphoma vs.
normal (p = 1.57x10-12).93 A total of 73 diffuse large B-cell lymphoma samples and
20 normal B-lymphocytes were analyzed using the Human Genome U133 Plus 2.0
Array. Lastly, in a study of 547 glioblastoma samples compared to 10 normal brain
samples, MEX3D was found to be 3.00-fold overexpressed in glioblastoma vs. normal
tissue (p = 8.65x10-9).94 These data are summarized in Figure 3.1 and Figure 3.2.

MEX3A-C are also overexpressed in many types of cancer
We also examined the expression levels of the other members of the MEX3
family, MEX3A-C. We found that these three genes displayed an expression profile
similar to that as MEX3D. We found that MEX3A was overexpressed in breast
cancer, melanoma, colorectal cancer, lung cancer, glioma, ovarian cancer, uterine
cancer, and prostate cancer. Notably, MEX3A is 19.6-fold overexpressed in basal cell
carcinoma compared to normal skin tissue (p = 1.47 x 10-7).
We found that MEX3B is overexpressed in breast cancer, uterine cancer, lung
cancer, and leukemia compared to normal tissue. Lastly, we examined the expression
profile of MEX3C in cancer compared to normal tissue, and found overexpression in
cervical cancer, glioblastoma, esophageal cancer, oral cancer, leukemia, sarcoma, and
gastric cancer. The cutoff values of p-value < 1.0 x 10-4 and fold-change > |2.0| were
used to search the Oncomine database.
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3.3 DISCUSSION

Human Mex-3A proteins, including hMex-3A, -3B, -3C and -3D, are located
on distinct chromosomes at 1q22, 15q25.2, 18q21.1 and 19p13.3, respectively (9). All
the four proteins contain two highly conserved KH domains specifically for RNA
binding and a RING finger domain in their carboxy- terminal region probably
involved in mediating protein-protein interactions (15-17). The similarity in structure
of the hMex-3 proteins implies that they may share certain similar biological
functions. In this study, we investigated the expression profiles of the MEX3 family
proteins in cancer compared to normal tissue. The data demonstrated that MEX3
family members are overexpressed in a broad range of types of cancer. Notably,
MEX3B is nearly 20-rfold overexpressed in basal cell carcinoma compared to normal
skin tissue. Furthermore, we found that MEX3D is overexpressed across a broad
range of cancers, including melanoma, sarcoma, glioma, pancreatic cancer, cervical
cancer, colorectal cancer, lymphoma, gastric cancer, and oral cancer.
Interestingly, one study associated the closely related gene MEX3A with
increased cell proliferation and migration in human gastric cancer cells.95 However,
the literature sheds little light otherwise on the role of the proteins in human and
especially their relation to disease development. This study is the first to describe
MEX3A-D expression in a variety of tumors as displaying possible oncogenic activity.
Few studies have looked at this gene family, and none have yet associated MEX3D
with cancer. The finding that MEX3D is overexpressed in many types of cancer is
alarming and warrants further investigation. These findings are crucial, as they point
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to clear evidence that MEX3 family members play a role in tumor development.
Future studies are needed to understand the mechanistic role of the proteins.
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Figure 3.1 Overexpression of MEX3D in tumors
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Figure 3.1 Overexpression of MEX3D in tumors
Using fold-change cutoff of > | 2.0 | and p-value cutoff of 1x10-4, the Oncomine
database was searched for cancer vs. normal expression data for MEX3D. The search
yielded studies in which MEX3D was only overexpressed.
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Figure 3.2 MEX3A-C are also overexpressed across tumor types
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Figure 3.2 MEX3A-C are also overexpressed across tumor types
Using fold-change cutoff of > | 2.0 | and p-value cutoff of 1x10-4, the Oncomine
database was searched for cancer vs. normal expression data for MEX3A (A), MEX3B
(B), and MEX3C (C). The search yielded studies in which MEX3A-C were only
overexpressed.
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Table 3.1 Expression profiles of MEX3A-D in cancer vs. normal tissue
Cancer

Expression
vs. normal

Cancer

Expression vs.
normal

MEX3A
Breast

2.09

BrainOligodendroglioma

Breast

3.85

Brain-astrocytoma

3.50

Melanoma-Basal Cell

19.57

Brain-Glioblastoma

3.01

Melanoma-Cutaneous 2.64

Brain-diffuse
astrocytoma

2.35

Colorectal

3.18

Ovarian-Endometriod

2.65

Rectal

5.38

Ovarian-Serous

2.03

Colon

4.89

Uterine

2.26

Lung-large cell

3.53

Prostate

2.20

Breast

2.17

Lung

2.48

Uterine

2.91

Leukemia

2.41

Cervical

2.57

Mouth

3.23

Brain-glioblastoma

2.59

Sarcoma-synovial

2.90

Brain-glioblastoma

3.42

Sarcoma-limpsarcoma

2.17

Brain-glioblastoma

2.05

Leukemia

2.58

Brainoligodenroglioma

2.56

Gastric

2.25

Esophagus

3.27

3.53

MEX3B

MEX3C

MEX3D
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Lymphoma

2.84

Sarcoma-fibrosarcoma

3.02

Cervical

2.80

Sarcoma-synovial

2.73

Melanoma-Cutaneous 4.41

Brain-glioblastoma

3.05

Melaonma-Benign

2.42

Pancreas

2.27

Renal

4.31

Tongue

2.12

Sarcoma-liposarcoma

3.11

Colorectal

2.59

Sarcomamyxofibrosarcoma

2.99

Rectal Adenoma

2.76

Sarcoma-myxoid

2.73

Colon

2.09

Sarcomafibrosarcoma

3.02

Gastric

2.52

Sarcoma-synovial

2.73

Prostate

2.10
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CHAPTER 4: MEX3D IS AN ONCOGENE IN GLIOMA

4.1 INTRODUCTION
RNA-binding proteins (RBPs) form a class of highly evolutionarily conserved
post-transcriptional regulators found in a variety of organisms. Recent studies
underscore the importance of such proteins in a variety of physiological functions,
including stem cell differentiation, embryogenesis, and cancer.32 MEX-3 is a
translational repressor and RNA-binding proteins originally discovered in C. elegans.
Vertebrates have four MEX-3 analogues, and are highly evolutionarily conserved
across species. The MEX-3 family plays an important role in a number of cellular
functions, but most recently they have been found to play a central role in cell
differentiation and cell renewal, and are thus of major concern to stem biology and
cell biology.45
Importantly, MEX-3 family members are highly evolutionarily conserved
throughout species. Phylogenetic analysis reveals that ancestral mex-3 underwent two
round of duplication after vertebrate lineage divergence, which accounts for the
presence of four homologues in both mice and humans.50 MEX-3 contains two K
homology (KH) domains that contain RNA-binding activity. However, vertebrates
contain an additional domain, perhaps a neo-functionalization that may have arisen
during species divergence, the carboxy terminus really interesting new gene (RING)
finger domain, which is absent in C. elegans. RING domains have been shown to
mediate E3 ubiquitin ligase activity. Such activity has been shown in MEX-3C, which
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is responsible for degradation of human leukocyte antigen serotype A2 (HLA-A2)
mRNA.51
While the primary function of MEX-3 proteins in humans is unknown, recent
evidence suggests they carry a role in cancer and other diseases, including
hypertension, metabolic diseases, and cancer.52-54 Interestingly, MEX3A
overexpression in an intestinal cell line lead to impaired differentiation and altered
polarity.55 Further, MEX-3 in C. elegans represses cell-cycle inhibitor cyclindependent kinase inhibitor-2 (CKI-2)56, whose human orthologues p21, p27, and p57
contain tumor suppressive activity.45 Furthermore, silencing of MEX-3C causes
chromosome mis-segregation, structural abnormalities, and DNA replication stress.45
Data from the Oncomine database (http://www.oncomine.com) strengthens the
possible role of MEX-3 family members in cancer, as there are large amounts of data
that suggest its overexpression in cancer compared to normal tissue.
MEX-3D, a member of the hMEX-3 family, is expressed in somatic tissue in
humans, contrasting with the expression profile of its analogues, which are restricted
to the embryo and the germ line. Interestingly, the Oncomine database reveals that
MEX-3D is highly overexpressed in a number of cancer samples compared to normal
tissue. Yet, there is a gross lack of understanding of the role of this protein in both
normal cell physiology and in cancer. The goal of this study was to determine the
effects of MEX3D in glioma. We found that MEX3D is 3.00-fold overexpressed in
glioma tissue compared to normal brain tissue. Kaplan-Meier analysis reveals that
overexpression of MEX3D also leads to poor survival in glioma patients. Furthermore,
we found that MEX3D leads to increased cell proliferation in A172 glioma cells.
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Concurrently, MEX3D also leads to decreased cell invasion in both A172 and U87
glioma cells. This study is the first to report the effect of MEX3D in cancer, and
describes MEX3D as a potential oncogene in glioma. Further studies are warranted to
examine the mechanistic role of MEX3D in gene regulation and in tumorigenesis.

4.2 RESULTS
MEX3D is overexpressed in glioma and leads to poor survivals.
In order to determine the clinical relevance of MEX3D in glioma, we searched the
Oncomine database for expression data in glioma compared to normal tissue. MEX3D is
highly overexpressed in glioblastoma. In a study of 547 glioblastoma samples compared to 10
normal brain samples, MEX3D was found to be 3.00-fold overexpressed in glioblastoma vs.
normal tissue (p = 8.65x10-9) (Figure 4.1).94 We also examined the effects of MEX3D
overexpression on overall survival in glioma patients. MEX3D expression data from n=273
glioma patients were analyzed using the Human Genome U133 Plus 2.0 Array. The KaplanMeier curve was calculated using a median-cutoff expression of 64.1 and two curves were
calculated: a high group (n=143) with MEX3D expression greater than the median 64.1
MEX3D expression value, and a low group (n=130) with MEX3D expression lower than the
median 64.1 expression value. After correcting for multiple comparisons using the Bonferoni
method, there was a statistically significant difference between the high- and low-MEX3D
expression profile groups (p = 6.2 x 10-3).

Differential methylation in MEX3D
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In order to understand the mechanism underlying the change in gene
expression in cancer, we searched for evidence of differential methylation in MEX3D
in glioma samples. We tested the methylation status of twelve matched glioma and
normal samples. The normal tissues came from the same patient and were adjacent
normal tissue to the tumor site. The analysis revealed that three CpG sites showed
significant differential methylation (p<0.05) between tumor and normal tissue. One
site in the body of MEX3D showed hypermethylation of 24% (Δβ=0.2477, p=3.4x104

) in tumor vs. normal tissue. Concurrently, a second site in the body of MEX3D was

hypomethlyated in tumor vs. normal tissue by 15.4% (Δβ= -0.154, p=0.001). A third
location in MEX3D in the 3’UTR was found to be hypomethylated by 9.5% (Δβ= 0.095, p=0.041).

MEX3D leads to increased cell proliferation in A172 glioma cells
As unregulated cell proliferation is a clear hallmark of cancer, we tested
whether knockdown of MEX3D has an effect on cell proliferation in vitro using RNA
interference against MEX3D in A172 glioma cells. As shown in Figure 4, the
chemically synthesized siRNA exhibited an efficient knockdown of MEX3D relative
to the siRNA control. There was approximately a 10-fold reduction in expression of
the knockdown compared to the control measured by qPCR. Remarkably, cell
proliferation assays showed that si-RNA knockdown of MEX3D leads to significant
decrease in cell proliferation in A172 glioma cells after five days compared to the
negative control si-RNA transfected cells (p <0.001) (Figure 4.2). The negative
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control exhibited normal cell growth, whereas the knockdown showed linear growth
at best from days 1-4.
MEX3D leads to decreased cell invasion in vitro
In order to test the effects of MEX3D on another hallmark of cancer, cell
invasion, we performed a cell invasion assay. MEX3D was knocked down in A172
glioma cells using si-RNA and U87 cells and compared to negative control si-RNA.
Unexpectedly, knockdown of MEX3D led to significant increases in cell invasion,
suggesting that MEX3D normally suppresses cell invasion. The relative fold increase
in MEX3D knockdown compared to the negative control in A172 cells was 4.80 (p =
0.003), and in U87 cells was 2.58 (p = 1.67 x 10-5) (Figure 4.5).

4.3 DISCUSSION
Human Mex3 proteins, including hMex3A, -3B, -3C and -3D, are located on
distinct chromosomes at 1q22, 15q25.2, 18q21.1 and 19p13.3, respectively (9). All
the four proteins contain two highly conserved KH domains specifically for RNA
binding and a RING finger domain in their carboxy- terminal region probably
involved in mediating protein-protein interactions (15-17). The similarity in structure
of the MEX3 proteins implies that they may share certain similar biological functions.
In the present study, one of the four proteins, MEX3D, was selected to investigate its
function in glioma cancer development and progression for the first time. The final
data demonstrated that a reduction in the MEX3D expression level led to a
suppression of cell growth. Furthermore, the silencing of MEX3D also resulted in a
increase in the invasion ability of gastric cancer cells. These findings shed light on the
role of MEX3 RNA-binding proteins, particularly for MEX3D in tumorigenesis.
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In recent years, RNA interference has been employed as a mature and
powerful strategy for exploring gene functions by downregulating the expression of
targeted genes. We applied this technique to specifically knockdown MEX3D in
A172 cells and in U87 cells. We found that MEX3D appears to promote cell
proliferation while limiting tumor invasion. Futhermore, we found that MEX3D is
overexpressed in glioma, and that overexpression of MEX3D in glioma patients leads
to poorer rates of survival.
While it is well known that methylation is an important epigenetic effect and
alters gene expression, the results of this study are inconclusive and cannot be
interpreted. Several reasons explain this. First, the quality of the samples was
compromised. The samples were stored in formalin fixed paraffin for a long period of
time, thus contaminating the samples and degrading them. This was evidenced by
heavy background noise in the data set. Further, a small sample size (n=12) limited
the power of the study. The methylation of MEX3D is an important effect that
warrants closer investigation and a bigger sample size.
The fact that MEX3D appears to promote cell proliferation while limiting
tumor invasion is somewhat paradoxical. However, the evidence we present of the
high level of over-expression of MEX3D as well as the poorer tumor survival in
glioma patients with high expression of MEX3D indicates that this protein plays a
major role in tumor development, especially in the context of glioma. Thus, we
conclude that MEX3D is a potential oncogene.
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In conclusion, our present study is the first to show that the knockdown of
hMex-3A using RNA interference can effec- tively inhibit cell proliferation and
migration in gastric cancer cells. These results further indicate that hMex-3A may
serve as a potential target for the therapy of gastric cancer, although additional studies
in vivo are necessary.
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Figure 4.1 MEX3D is overexpressed in glioma and leads to poor survival in
glioma patients
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Figure 4.1 MEX3D is overexpressed in glioma and leads to poor survival in
glioma patients
Oncomine database reveals that MEX3D is 3.00-fold overexpressed in glioma tumors
vs. normal brain tissue (p = 8.65 x 10-9) (A). Using median-expression cutoffs in the
Kaplan Meier survival analysis, overexpression of MEX3D is associated with poorer
survival in all glioma patients (B). The red, top line represents lower expression of
MEX3D, whereas the bottom blue line represents higher expression of MEX3D.
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FIGURE 4.2 Methylation of CpG sites in MEX3D in glioma vs. normal samples
30%
25%
20%
15%
10%
5%
0%
-5%

3'UTR

Body

Body

-10%
-15%
-20%

73

Figure 4.2 Methylation of CpG sites in MEX3D in glioma vs. normal samples
Analysis of methylation status of MEX3D reveals that one site in the body of MEX3D
showed hypermethylation of 24% (Δβ=0.2477, p=3.4x10-4) in tumor vs. normal tissue.
Concurrently, a second site in the body of MEX3D was hypomethlyated in tumor vs.
normal tissue by 15.4% (Δβ= -0.154, p=0.001). A third location in MEX3D in the
3’UTR was found to be hypomethylated by 9.5% (Δβ= -0.095, p=0.041).
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Figure 4.3 Knockdown of MEX3D in A172 cells
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FIGURE 4.3 Knockdown of MEX3D in A172 cells
si-RNA knockdown of MEX3D. Expression levels were quantified using the 2∆∆Ct

method with normalization to the stably expressed gene GAPDH, where ∆∆Ct =

(Ct:siRNA-NC_A172 – Ct:GAPDH_A172) – (Ct:siRNA-MEX3D_A172 – Ct:APDH _A172). Error bars
represent the standard deviation of the CT values.
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Figure 4.4 MEX3D knockdown decreases cell proliferation in A172 glioma cells
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Figure 4.4 MEX3D knockdown decreases cell proliferation in A172 glioma cells
MEX3D was knocked down in A172 glioma cells using siRNA against MEX3D.
Knockdown of MEX3D (bottom dashed line) leads to significant decrease in cell
proliferation in A172 glioma cells after five days compared to the negative control siRNA transfected cells (top solid line) (p <0.001). The experiment was performed in
triplicates, and the error bars represent the standard deviation between the triplicate
experiments.
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Figure 4.5 MEX3D knockdown increases cell invasion in A172 cells and U87
cells
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Figure 4.5 MEX3D knockdown increases cell invasion in A172 cells and U87
cells
MEX3D was knocked down using si-RNA against MEX3D in A172 cells and in U87
cells. Negative control si-RNA (NC) served as the control. The cells were transfected
and incubated for 24 hours. A. Ten random fields from each of the invasion assays
were selected for cell counting using phase-contrast microscopy. B. Error bars
represent the standard deviation between the ten fields. Statistical significance of thde
difference between the NC and the knockdown was determined using the Students ttest.
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CHAPTER 5: CONCLUSIONS
The control of gene expression is pivotal in the context of molecular
pathogenesis of a number of diseases, and thus is of critical relevance to public health.
An array of cellular tools exist in controlling gene expression, including epigenetic
effects, non-coding RNAs, and RNA-binding proteins. These tools are critical tools to
the modern of public health, and are used in tandem with population-based studies.
This work focuses on specific examples of non-coding RNAs and RNA-binding
proteins, describing the effects of microRNA-618 and MEX3D, a post-transcriptional
regulator, in cancer.
MicroRNAs (miRNAs) form a class of highly conserved endogenous RNAs
that inhibit gene expression and may act as oncogenes or as tumor suppressors,
regulating extensive cancer-related gene networks. Here, we showed the association
between a single miRNA, miR-618, and cancer-related pathways in HeLa cells. MiR618 was identified as a potentially oncogenic microRNA, controlling a number of
cancer-related gene networks and pathways. Gain-of-function analysis reveals
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differential expression of 110 transcripts following miRNA-618 transfection.

Notably, three upregulated genes are well-studied oncogenes—KIT, JUN, and
FOSB—and three downregulated genes are well-known tumor suppressors—PTPRO,
STK11/LKB1, and IGFBP5. Interestingly, investigation using the Ingenuity Pathway
Analysis software tool reveals alterations in multiple cancer-related and cell cyclerelated networks, including upregulated oncogenes in the top identified network
“Post-translational modification, cellular development, cellular growth and
proliferation” following miR-618 transfection. Further, miR-618 expression analysis
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shows overexpression in HeLa cells compared to normal cervical cells. Our findings
present evidence for a novel oncogenic miRNA, miR-618, that is involved in cancerrelated gene networks and is overexpressed in cancer.
RNA binding proteins also play a critical role in regulating gene expression,
and are often critical in tumor development. This work also examined the role of a
novel post-transcriptional regulator, MEX3D, in cancer. 97 The Oncomine online
database reveals that MEX3D is overexpressed in a number of solid tumors, notably
in glioma. MEX3D is 3.01-fold overexpressed in glioma cells compared to noncancerous, normal tissue. Kaplan-Meier survival analysis reveals that higher
expression of MEX3D leads to poorer overall survival in overall glioma patients.
Lastly, in a pilot case-control study of twelve glioma biopsies, we examined the
effects of methylation in CpG sites in the MEX3D gene. The results were unclear, as
we found a 3’UTR site that was 9.5% hypermethylated compared to normal tissue, a
site in the body of the gene that was 24.8% hpyermethylated, and second site in the
body that was 15.4% hypomethylated compared to normal tissue..
Phenotypic studies reveal that MEX3D is responsible for two cancer
phenotypes. Knockdown of MEX3D leads to increased cell proliferation and
decreased cell invasion, suggesting that overexpression of MEX3D is responsible for
increased cell proliferation and decreased cell invasion.
This study is the first to describe the effects of miR-618 and of MEX3D in
cancer. The findings presented in this work lay the foundation for further mechanistic
studies of miR-618 and MEX3D. More work is needed to identify the mechanisms of
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oncogenesis controlled by these molecules. Our study indicates that miR-618 may be
a biomarker for several types of cancer and warrants further investigation.
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CHAPTER 6: Materials and methods

6.1 Cell culture and miRNA transfection (Chapters 2 and 4)
HeLa cells (American Type Culture Collection) were cultured in Dulbecco’s
modified Eagle medium (Invitrogen) with 10% fetal bovine serum (Invitrogen) and
1% penicillin/streptomycin (Sigma-Aldrich). A172 cells will be purchased from
ATCC (Manassas, VA) and maintained as monolayer cultures in 25 cm2 polystyrene
flasks in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10%
fetal bovine serum (FBS). Cells will be incubated at 37ºC in a humid atmosphere
containing 5% CO2 and subcultured every 2-3 days.

6.2 miRNA transfection (Chapter 2)
A synthetic miRNA mimic of hsa-miR-618 (5’AAACUCUACUUGUCCUUCUGAGU-3’) was synthesized by Qiagen for
transfection. Cells were transfected with either the miR-618 mimic or a scrambled
negative control (Qiagen) using the Lipofectamine RNAiMAX transfection reagent
(Invitrogen), according to the manufacturer’s protocol. 120 pmol of miR-618 or
negative control was mixed with 20 µl of RNAiMAX reagent and 2 ml OPTI-MEM
(Invitrogen). The mixtures were transfected with ~100,00 cells in 12-well plates, and
cells were harvested 48 hours post-transfection. RNA was subsequently extracted for
analysis using the RNeasy Mini Kit (Qiagen), according to the manufacturer’s
protocol.
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6.3 Genome-wide expression microarray (Chapter 2)
Gene expression differences in cells transfected with the miR-618 mimic were
interrogated by whole genome microarray (Agilent, Inc 41k chip, performed by
MoGene). The miRNA transfection and microarray were conducted in two
independent biological replicates. Due to the multiple comparisons inherent in the
microarray analysis, the false discovery rate (FDR) method as described by
Benjamini and Hochberg was applied in order to obtain an adjusted p-value (Q).98
Transcripts with inadequate signal intensity (Intensity < 50) were discarded.
Expression differences were considered to be statistically and biologically significant
at Q < 0.05 and fold change ≥ |2|.

6.4 Network Analysis (Chapter 2)
Genes that were differentially expressed from the miR-618 transfection were
investigated for functional interrelatedness using the IPA software tool (Ingenuity
Systems). This tool elucidates networks and functionality by using information in the
Ingenuity Pathways Knowledge Base, which is a database of known functional
interactions that have been previously identified in peer-reviewed publications.99
Statistical significance was obtained by performing a Fisher’s exact test based on the
hypergeometric distribution for each identified network to calculate the likelihood of
obtaining at least the same number of related expressed genes by chance for the input
gene set.
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6.5 Expression analysis of miR-618 (Chapter 2)
Total RNA from HeLa cells and End1 cells (American Type Culture
Collection) was isolated using the miRNeasy Mini Kit (QIAGEN), with on-column
DNA digestion. To determine levels of mature miRNA, polyadenylated mature
miRNA sequences were first generated and converted to cDNA using the NCode
miRNA First-Strand cDNA Synthesis Kit (Invitrogen). The cDNA was then
amplified using a custom miR-618-specific forward primer (5’AAACTCTACTTGTCCTTCT -3’) and a universal reverse primer targeting on the
polyadenylated region of the miRNA. Mature miRNA levels in HeLa cells relative to
End1 cervical cells were assessed using the 2-∆∆Ct method with normalization to the
stably expressed ncRNA U6B, where ∆∆Ct = (Ct:miR-618_HeLa – Ct:U6B_HeLa) – (Ct:LmiR618_End1

– Ct:U6B_End1). All qPCR reactions were performed in triplicate on an ABI

7500 Fast Real-Time PCR instrument (Applied Biosystems) using the Kapa
Biosystems SYBR Fast qPCR kits (Kapa Biosystems) according to the
manufacturer’s protocols.

6.6 Oncomine Database Search (Chapters 3 and 4)
In order to determine differential expression of MEX3D in cancer vs. normal
tissue, the Oncomine Database was searched on Sunday, March 30, 2014 using the
search terms “MEX3D” and filtering for cancer vs. normal analysis
(http://www.oncomine.org/). The following filters were added: threshold fold change
of |2.0| and a threshold p-value of 1x10-4.
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6.7 Kaplan-Meier curve (Chapter 4)
MEX3D expression data from 273 glioma patients were analyzed using the Human Genome
U133 Plus 2.0 Array. The Kaplan-Meier curve was calculated using a median-cutoff
expression of 64.1 and two curves were calculated: a high group (n=143) with MEX3D
expression greater than the median 64.1 value, and a low group (n=130) with MEX3D
expression lower than the median 64.1 expression value. The Bonferoni method was to
correct for multiple comparisons.

6.8 MEX3D methylation analysis (Chapter 4)
The Illumina Custom Model, as implemented in the Illumina GenomeStudio
software, was used to assess the statistical significance of methylation differences
between glioma cases and controls at each CpG site. This model operates under the
assumption that the methylation value β is normally distributed at each locus. The
variance function is estimated for all values of β by repeatedly measuring loci with
known methylation fractions ranging from 0 to 1, and then fitting a parabola to the
standard deviation as a function of β. The standard deviation estimate is then given by
s = Aβ2 + Bβ + C, where A = -0.1511, B = 0.1444, and C = 0.01646.
P-values were calculated using the following formula:

|βcond  -‐  βref|
p  =  z %s2ref s2cond4
N +N
ref

cond

where z denotes the standard score of a two-sided normal probability distribution, βref
and βcond denote the average β values for the reference (normal tissue controls) and
condition (glioma tumor samples) groups, s2ref and s2cond denote the variances of βref
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and βcond, and Nref and Ncond denote the sample sizes of the reference and condition
groups. Due to the multiple comparative nature of our epigenome-wide analysis, Pvalues generated by the array were corrected for multiple comparisons using the
Benjamini-Hochberg method

100

based on the number of CpG sites measured

(485,577) to minimize the probability of false positives. Only CpG sites exhibiting
methylation differences with corrected P-values of <0.05 were considered as
significantly altered.

6.9 RNA interference and cell transfection (Chapter 4)
In order to suppress MEX3D expression in glioma cells, MEX3D-specific
small interference RNA (siRNA) was chemically synthesized from Invitrogen
(Catalog no. 1299001). A negative control siRNA served as the control for the cancer
phenotype assays (Invitrogen). A172 cells cells will be reverse transfected in 12-well
plates with either siRNA or the siRNA control using LipofectAMINE RNAiMAX
transfection reagent (Invitrogen, Carlsbad, CA). Approximately 25,000 cells
suspended in 10% FBS-supplemented DMEM will be added to a pre-incubated
mixture of RNAiMAX (1 µl) and RNA oligo in each well to a final oligo
concentration of 25 nM. Wells will be incubated at 37ºC and 5% CO2 for 72 hours
prior to RNA isolation (RNeasy Mini Kit, QIAGEN, Valencia, CA). All transfections
were conducted in biological triplicate. Total RNA from A172 cells (American Type
Culture Collection) was isolated using the RNeasy Mini Kit (QIAGEN), with oncolumn DNA digestion. To determine levels of mature mRNA, polyadenylated
mature mRNA sequences were first generated and converted to cDNA using the
NCode mRNA First-Strand cDNA Synthesis Kit (Invitrogen). The cDNA was then
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amplified using a custom MEX3D specific forward primer (5’CCAGGGCTGCAAGATCAAG-3’). Mature mRNA levels in A172 cells were
assessed using the 2-∆∆Ct method with normalization to the stably expressed gene
GAPDH, where ∆∆Ct = (Ct:siRNA-NC_A172 – Ct:GAPDH_A172) – (Ct:siRNA-MEX3D_A172 –
Ct:APDH _A172). All qPCR reactions were performed in triplicate on an ABI 7500 Fast
Real-Time PCR instrument (Applied Biosystems) using the Kapa Biosystems SYBR
Fast qPCR kits (Kapa Biosystems) according to the manufacturer’s protocols.

6.10 Cell proliferation assay (Chapter 4)
Effects of MEX-3D on cell proliferation will be measured using a cell
proliferation assay kit from Invitrogen (Cat. No C35006). This compares MEX-3D
knockdown in A172 cells to A172 cells treated with the negative control siRNA. This
assay measures cell proliferation by quantifying DNA to indicate a relative cell
number, and will be performed according to the manufacturer’s protocols. Each time
point was measure in triplicate and were measured in 24-hour intervals.

6.11 Cell invasion assay (Chapter 4)
A172 cells and U87 cells were seeded into the upper wells of 24-well
Transwell plates on Matrigel-coated (BD Biosciences Inc., San Jose, CA, USA) 8-µm
poly(ethylene terephthalate) membranes (Millipore Corpo., Billerica, MA , USA) in
DMEM without fetal bovine serum (FBS). The lower wells contained complete
medium with 10% FBS. After 48 h of incubation in a humidified atmosphere with
5% CO2, the contents of the upper well content were removed using Q-tips. The
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invasion chambers were processed following the manufacturer’s protocols, and the
migrated cells were stained with haematoxylin (??). Ten random fields from each of
the invasion assays were selected for cell counting using phase-contrast microscopy.

6.12 Statistical analysis
With the exception of differential gene expression analysis, network analysis,
and methylation analysis using the statistical methods described above, all other
statistical analyses were evaluated using the Student’s t-test. P <0.05 was considered
to indicate a statistically significant difference.
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CHAPTER 7: SUPPLEMENTARY INFORMATION

TABLES
Supplementary Table S1. All identified differentially expressed genes by miR-618
transfection with expression fold changes ≥ |2|
Gene Symbol

Descriptiona

Fold changeb

AU145408

Unknown function

5.24

A_24_P942036

Unknown function

4.66

A_32_P6841

Unknown function

4.46

AK026750

Unknown function

4.38

CCDC66

4.30

A_32_P233713

Coiled-coil domain containing 66; encoded protein
linked to progressive retinal atrophy
Unknown function

TEX13B

Testis expressed 13b

4.04

A_32_P4882

Unknown function

3.79

FOSB

FBJ murine osteosarcoma viral oncogene homolog B.
Encodes protein that can dimerize with proteins of the
FUN family. Implicated in cell proliferation,
differentiation, and transformation.
Unknown function

3.62

Protocadherin 1; encodes membrane protein found at
cell-cell boundaries.
Hemoglobin, beta pseudogene 1.

3.52

3.41

NM_052958

Nuclear apoptosis inducing factor 1; encoded protein
inhibits tumor cell proliferation by inducing apoptosis.
Unknown function

CA441361

Unknown function

3.16

FA2H

Fatty acid 2-hyrdoxylase. Encoded protein catalyzes
synthesis of 2-hydroxysphingolipids.

3.13

A_24_P611965
PCDH1
HBBP1
NAIF1

4.06

3.59

3.49

3.36
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KRT18

Keratin 18; encodes type I intermediate filament chain
keratin 18. Expressed in epithelial tissues and mutations
in KRT18 have been linked to cryptogenic cirrhosis.
Unknown function

2.99

Collagen, type VIII alpha 2. This encoded protein is a
major component of the basement membrane of corneal
epithelium.
Sterile alpha motif domain containing 9-like

2.90

2.79

BC063641

Jun proto-oncogene; Putative transforming gene of
avian sarcoma virus 17. Encoded gene interacts with
specific DNA to regulate gene expression.
Potassium voltage-gated channel, Isk-related family,
member 4. Encoded protein is a type I membrane
protein with a potassium channel.
Unknown function

W95609

Unknown function

2.67

BIK

2.66

AI263083

BCL2-interacting killer (apoptosis-inducing). Encoded
protein has pro-apoptotic activity and its expression is
suppressed in the presence of survival-promoting
proteins.
Unknown function

ZBED2

Zinc finger, BED-type containing 2

2.59

THC2340539

Unknown function

2.57

IL22RA1

2.52

ENST00000379557

Interleukin 22 receptor, alpha 1. Encoded protein
belongs to class II cytokine receptor family and has
been shown to be a receptor for IL22.
Actin binding LIM protein family, member 3; protein
contains LIM domain, double zinc finger. It plays roles
in embryonic development, cell lineage determination,
and cancer.
Unknown function

SRRM3

Serine/arginine repetitive matrix 3

2.50

THC2442829

Unknown function

2.44

THC2409451

Unknown function

2.40

BF899060
COL8A2
SAMD9L
JUN
KCNE4

ABLIM3

2.93

2.85

2.75
2.67

2.66

2.50

2.50
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ENST00000320662

Unknown function

2.39

THC2316768

Unknown function

2.38

CPM

Carboxypeptidase M; encoded protein is a membranebound arginine/lysine carboxypeptidase and is
associated monocyte differentiation
Endothelin 2; encodes member of endothellin protein
family of secretory vasoconstrictive peptides.
Decorin; encoded protein is a small cellular or
pericellular matrix proteoglycan that is a component of
connective tissue, binding to type I collage fibrils and
playing a role in matrix assembly.
Unknown function

2.38

Potassium inwardly-rectifying channel, subfamily J,
member 10. Encodes potassium channel that allows
potassium to flow into, rather than out of, a cell.
Unknown function

2.27

2.26

BE671182

Cadherin 7, type 2; encoded protein is membrane
protein that is a calcium dependent cell-cell adhesion
glycoprotein
Angiogenin, ribonuclease, RNase A family, 5; encodes
protein that strongly mediates blood vessel formation
Unknown function

THC2398758

Unknown function

2.25

KREMEN2

2.25

DESI2

Kringle containing transmembrane protein 2. Encodes a
high-affinity dickkopf homolog 1 (DKK1)
transmembrane receptor and complexes with DKK1
And lipoprotein receptor-related protein 6 (LRP6) to
induce rapid endocytosis and removal of LRP6 from
plasma membrane.
Desumoylating isopeptidase 2

THC2436337

Unknown function

2.21

TM4SF1

Transmembrane 4L six family member 1; encodes
protein of transmembrane 4 superfamily that mediates
signal transduction to play a role in regulating cell
development, activation, growth, and motility.
v-KIT Hardy-Zuckerman 4 feline sarcoma viral
oncogene homolog; encodes human homolog of protooncogene c-kit. Aberrant expression associated with

2.21

EDN2
DCN

BC038972
KCNJ10
AA586832
CDH7
ANG

KIT

2.36
2.35

2.27

2.26

2.25
2.25

2.22

2.20
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A_24_P919283

cancer.
Annexin A8; encodes protein Ca2+ and phospholipid
binding proteins. Encoded protein may function as an
anticoagulant that indirectly inhibits thromboplastinspecific complex. Overexpression of ANXA8 has been
associated with acute myelocytic leukemia.
Mitogen-activated protein kinase 4; activated MAPK4
translocates to nucleus to phosphorylate nuclear targets.
Serum/glucocorticoid regulated kinase family, member
3; encoded kinase phosphorylates several target proteins
and plays role in neutral amino acid transport and
activation of potassium and chloride channels.
Unknown function

NGEF

Neuronal guanine nucleotide exchange factor

FBXO2

AI915259

F-box protein 2; encodes protein involved in
2.15
phosphorylation-dependent ubiquitination.
Lengsin, lens protein with glutamine synthetase domain; 2.14
encoded protein is localized to the lens and by be
associated with cataract disease.
Unknown function
2.14

IFI27

Interferon alpha-inducible protein 27

2.14

THC2282944

Unknown function

2.13

ENST00000375256

Unknown function

2.12

N34499

Unknown function

2.11

ENST00000302001

Unknown function

2.10

SMIM15

Small integral membrane protein 15

2.10

BI963219

Unknown function

2.08

AF086329

Unknown function

2.08

PIGZ

Phosphatidylinosital glycan anchor biosynthesis, class
Z; encodes protein that localizes to the endoplasmic
reticulum and is involved in
glycosylphosphatidylinosital anchor biosynthesis.
Unknown function

2.05

ANXA8

MAPK4
SGKL

LGSN

AW440350

2.19

2.17
2.17

2.15
2.15

2.05
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THC2265157

Unknown function

2.05

H43551

Unknown function

2.04

BM504117

Unknown function

2.04

AF159295

Unknown function

2.04

MX1

2.04

PRLH

Myxovirus resistance 1, interforn-inducible protein p78;
encoded protein is responsible for specific antiviral state
against influenza virus infection.
Fibroblast growth factor binding protein 1; Encodes
secreted fibroblast growth factor carrier protein that
plays major role in cell differentiation, proliferation, and
migration. FGFBP1 has been linked to cancer, including
pancreatic and colorectal adnenocarcinoma.
Macrophage migration inhibitory factor (glycosylationinhibiting factor; encodes lymphokine involved in cellmediated immunity, immunoregulation, and
inflammation.
Ankyrin repeat and SOCS box containing 4; encoded
protein is member of ankyrin repeat and SOCS boxcontaining (ASB) family of proteins.
Ribonuclease, RNase A family, 4; encoded protein is
member of pancreatic ribonuclease family. Plays
important role in mRNA cleavage and has marked
specificity towards the 3’ side of uridine nucleotides.
ATPase, aminophospholipd transporter, class I, type 8B,
member 3; encoded protein belongs to family of P-type
cation transport ATPases, and to the subfamily of
aminophospholipid-transporting ATPases.
v-maf musculoaponeurotic oncogene (avaian); MAFA is
a transcription factor that binds RIPE3b, a conserved
enhancer element that regulates pancreatic beta celspecific expression of the insulin gene.
Prolactin releasing hormone

A_24_P375751

Unknown function

-2.05

PTPRO

Protein tyrosine phosphatase, receptor type, O; encodes
member of R3 subtype family of receptor-type protein
tyrosine phosphatases. This gene is believed to be a
tumor suppressor, and its decreased expression has been
associated with several types of cancer.
Platelet-derived growth factor receptor, alpha
polypeptide; encoded protein is a cell surface tyrosine

-2.07

FGFBP1

MIF

ASB4
RNASE4

ATP8B3

MAFA

PDGFRA

2.03

2.01

2.01
2.01

2.00

-2.02

-2.02

-2.10
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TNRC18

kinase receptor for members of the platelet-derived
growth factor family. These growth factors are mitogens
for mysenchymal clles. Mutations in this gene have
been associated with tumor progression.
Trinucleotide repeat containing 18

-2.11

BC013423

Unknown function

-2.17

BQ015140

Unknown function

-2.17

DHH

Desert hedgehog; this gene encodes member of
hedgehog family that encodes signaling molecules. The
protein may be involved in male gonadal differentiation
and perineurial development.
Unknown function

-2.17

A_24_P862251
HAUS1
HOX-AS3
GPHB5

-2.18

HAUS augmin-like complex, subunit 1; encoded protein -2.18
is a microtubule-binding complex involved in
microtubule generation within the mitotic spindle.
HOXB cluster antisense RNA3
-2.24
-2.29

SLC35F5

Glycoprotein hormone beta 5; encodes cysteine knotforming polypeptide and a subunit of the dimeric
glycoprotein hormone family.
Solute carrier family 35, member F5

ENST00000074056

Unknown function

-2.32

NM_173573

Unknown function

-2.34

ARTN

Artemin; this protein is a member of the glial cell linederived neurotrophic (GDNF) family of ligands and has
neurotrophic properties.
Serine/threonine kinase 11; regulates cell polarity and
functions as a tumor suppressor. Mutations in the gene
associated Peutz-Jeghers syndrome and other
neoplasms.
Leucine rich repeat containing 15

-2.37

STK11

LRRC15
ARHGAP27
CLDN5
C1QTNF5

-2.31

-2.38

-2.40

Rho GTPase activating protein 27; encodes a GTPases
-2.44
that is involved in many cellular processes.
Claudin 5; encodes integral membrane protein and
-2.47
forms tight junctions. Mutations in this gene have been
associated with velocardiofacial syndrome.
C1q and tumor necrosis factor related protein 5; encodes -2.47
protein that may be a component of basement
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BX105253
MATN3

membranes and may play role in cell adhesion.
Mutations in this gene have been associated with lateonset retinal degeneration
Unknown function

-2.65
-2.69

A_32_P185089

Matrilin 3; encodes member of von Willebrand factor A
domain containing family of proteins. Thought to be
involved in forming filamentous networks in the
extracellular matrices in several tissues. Mutations in
this gene result in multiple epiphyseal dysplasia.
Glycolipid transfer protein; encoded protein accelerate
transfer of various glycosphingolipids and
glyceroglycolipids between membranes.
Unknown function

EFCAB4A

EF-hand calcium binding domain 4a

-3.00

CBX5

Chromobox homolog; encodes member of
-3.36
heterochromatin protein family. Enriched in the
heterochromatin and associated with centromeres. Can
bind to histones via methylated lysine residues and is
involved in the formation of functional kinetochore.
Arginine vasopressin. This encoded proteins is a
-3.62
posterior pituitary hormone that acts as a growth factor
and is involved in antidiuretic activity in the kidney. It
can also cause vasoconstriction of the peripheral vessels.

GLTP

AVP

a

-2.79
-2.80

Gene function description was summarized from information obtained from database Entrez Gene

Summary.
b

All fold changes are statistically significant (Q<0.05; False Discovery Rate (FDR) <0.05).
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Supplementary Table S2. Identified cancer-related differentially expressed miR-618
targets
Gene name

Expression

Cancer-related functionsb

fold changesa
ANG

2.25

Tumorigenesis of cervical cancer cell lines, mammary tumor

ANXA8L2

2.19

Carcinoma, adenocarcinoma, ovarian cancer; gonadal tumor

BIK

2.66

Carcinoma, adenocarcinoma, uterine cancer

C8ORF8/SGK1 2.17

Mammary tumor skin cancer

CDH7

2.26

Skin cancer

CLDN5

-2.47

Carcinoma, adenocarcinoma, uterine cancer

DCN

2.35

Mammary tumor, arrest in G1 phase of colon carcinoma cells

DESI2

2.22

Mammary tumor, carcinoma

FGFBP1

2.03

Epidermal hyperplasia

FOSB

3.62

Mammary tumor, carcinoma, ovarian cancer, gonadal cancer

HMGB1

2.04

HUWE1

2.04

IFI27

2.14

IGFBP5

-2.02

IL22RA1

2.52

Carcinoma, liver cancer, large cell lymphoma, Non-Hodgkin’s
lymphoma, Hodgkin’s lymphoma
Mammary tumor, carcinoma, head and neck cancer, liver,
cancer, benign neoplasia, pancreatic tumor, lung cancer,
pancreatic cancer, carcinoma in the lung, thyroid carcinoma
Carcinoma, ovarian cancer, gonadal cancer, head and neck
cancer, skin squamous cell carcinoma
Carcinoma, adenocarcinoma, head and neck cancer, benign
neoplasia, pancreatic tumor, binding of mammary tumor cells,
leiomyomatosis, mucoepidermoid carcinoma, metastatic
colorectal cancer
Carcinoma

JUN

2.79

Mammary tumor, carcinoma, ovarian cancer, gonadal tumor,
uterine cancer, skin cancer, squamous cell tumor, large-cell
lymphoma, Non-Hodgkin’s lymphoma, non-Hodgkin’s
lymphoma, head and neck cancer, benign neoplasia, lung
cancer, skin squamous cell carcinoma, leiomyomatosis,
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leukemia, bone marrow cancer
Leukemia, bone marrow cancer

KCNE4

2.75

KIT

2.20

KRT18

2.99

MAFA

-2.02

Mammary tumor, carcinoma, adenocarcinoma, ovarian cancer,
gonadal cancer, skin cancer, liver cancer, large-cell
lymphoma, Non-Hodgkin’s lymphoma, head and neck cancer,
benign neoplasia, pancreatic tumor, lung cancer, carcinoma in
lung, thyroid carcinoma, leiomyomatosis, leukemia, bone
barrow cancer, dysgerminoma, uticaria pigmentosa,
chordoma, aggressive fibromatosis, mixed germ cell tumor,
seminoma, melanoma, sporadic mastocytosis, sarcoma,
systemic
mastocytosis,
islet-cell
carcinoma,
neurofibrosarcoma, primary peritoneal cancer, gastrointestinal
stromal tumor, Fallopian tube cancer, testicular cancer
Carcinoma, adenocarcinoma, uterine cancer, head and neck
cancer, mucoepidermoid carcinoma, metastatic colorectal
cancer
Carcinoma, squamous cell tumor

MATN3

-2.70

Carcinoma, liver cancer

MIF

2.01

Carcinoma, ovarian cancer, gonadal cancer, sarcoma

MX1

2.04

Epidermal hyperplasia

PDGFRA/B

-2.10

RNASE4

and Mammary tumor, carcinoma, adenocarcinoma, ovarian cancer,
gonadal cancer, liver cancer, head and neck cancer, benign
+2.04,
neoplasia, pancreatic tumor, lung cancer, pancreatic cancer,
carcinoma in lung, leiomyomatosis, leukemia, bone marrow
respectively
cancer, sarcoma, systemic mastocytosis, islet-cell carcinoma,
neurofibrosarcoma, primary peritoneal cancer, gastrointestinal
stromal tumor, Fallopian tube cancer
2.01
Carcinoma, adenocarcinoma, uterine cacner

STK11/LKB1

-2.38

TM4SF1

3.16

Carcinoma, adenocarcinoma, gonadal tumor, uterine cancer,
skin cancer, squamous cell tumor, pancreatic tumor, lung
cancer, pancreatic cancer, carcinoma in lung, testicular cancer,
adenoma malignum, Peutz Jagher syndrome
Carcinoma, adenocarcinoma, skin cancer, liver cancer,
metastatic colorectal cancer

a

All fold changes have a Q value of <0.05.

b

All associations between the transcript and disease have a p-value of <0.05.
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Supplementary Table S2: Affected genes related to hepatotoxicity and
hepatocellular carcinoma
Gene

Effect

Fold changea

TM4SF1

Upregulated

3.16

KIT

Upregulated

2.20

PDGFRB

Upregulated

2.14

HUWE1

Upregulated

2.04

HMGB1

Upregulated

2.04

PDGFRA

Downregulated

-2.10

MATN3

Downregulated

-2.70

a

Overlap p-value: 5.72 x 10-3
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Supplementary Figure S1: Secondary structure prediction of pre-miR-618.
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Supplementary Figure S1: Predicted secondary structure of pre-miR-618.
Mature miR-618 is highlighted in red. Base pairs are colored according to the
probability of predicted accuracy. Red represents >99% probability, whereas blue
represents 50-60% accuracty. Secondary structure generated using RNAstructure.101
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Supplementary Figure S2: Differentially expressed transcripts following miR-618
transfection in the “Cellular movement, cell death and survival, and cell cycle”
network.
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Supplementary Figure S2: Differentially expressed miR-618 targets in the
“Cellular movement, cell death and survival, and cell cycle” network. This
network was identified by the Ingenuity Pathway Analysis software as significantly
associated with the set of transcripts with altered expression following the
introduction of pre-miR-618 (pooled p-value = 8.61 x 10-7 and FC ≥ |2|).
Overexpressed transcripts are indicated in red, and underexpressed transcripts are
indicated in green.
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